Standout Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-posi... 2010 2026 2015 2020 5.1k
  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010)
    Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet
  2. Gastric cancer (2020)
    Elizabeth Smyth, Magnus Nilsson et al. The Lancet
  3. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016)
    Florian Lordick, C. Mariette et al. Annals of Oncology
  4. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer (2010)
    Marc Peeters, Timothy Price et al. Journal of Clinical Oncology
  5. Oesophageal cancer (2017)
    Elizabeth Smyth, Jesper Lagergren et al. Nature Reviews Disease Primers
  6. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial (2009)
    Gunnar Folprecht, Thomas Gruenberger et al. The Lancet Oncology
  7. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial (2013)
    Florian Lordick, Yoon‐Koo Kang et al. The Lancet Oncology
  8. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    Florian Lordick, Fátima Carneiro et al. Annals of Oncology
  9. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial (2007)
    Florian Lordick, Katja Ott et al. The Lancet Oncology
  10. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954 (2010)
    Christoph Schuhmacher, Stephan Gretschel et al. Journal of Clinical Oncology
  11. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus (2018)
    Manish A. Shah, Takashi Kojima et al. JAMA Oncology
  12. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023)
    Kohei Shitara, Florian Lordick et al. The Lancet
  13. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    Radka Obermannová, María Alsina et al. Annals of Oncology
  14. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma (2021)
    Uğur Şahin, Ö. Türeci et al. Annals of Oncology
  15. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm (2021)
    Yoshiaki Nakamura, Akihito Kawazoe et al. Nature Reviews Clinical Oncology
  16. Primary and metastatic peritoneal surface malignancies (2021)
    Delia Cortés‐Guiral, Martin Hübner et al. Nature Reviews Disease Primers
  17. Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise—Evidence and Implications (2023)
    Irit Ben‐Aharon, Hanneke W.M. van Laarhoven et al. Cancer Discovery
  18. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). (2024)
    Jens Hoeppner, Thomas Brunner et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 7 from Science/Nature 94 standout
Sub-graph 1 of 15

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Colorectal cancer
2024 Standout
11 intermediate papers

Works of Florian Lordick being referenced

Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases.
2022
Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555)
2012
and 5 more

Author Peers

Author Last Decade Papers Cites
Florian Lordick 15458 12774 10573 507 27.2k
Atsushi Ohtsu 16772 13908 9640 523 26.2k
Hyun Cheol Chung 13659 14781 6961 577 26.9k
Yung‐Jue Bang 16587 20426 7405 602 36.1k
Andrés Cervantes 9130 17546 8193 459 26.9k
Jaffer A. Ajani 26242 16398 20687 923 44.0k
Jean‐Pierre Pignon 15967 14491 8696 305 30.3k
John Zalcberg 7808 9455 5365 398 18.1k
Olivier Bouché 9242 18148 7789 410 24.6k
Ian Judson 16160 10674 4927 402 27.4k
Robert A. Wolff 8251 21227 9068 455 28.2k

All Works

Loading papers...

Rankless by CCL
2026